The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease

Kidney International

Volumn 67, Issue 1, 2005, Pages 265-271

  Jafar, Tazeen H ^a   Stark, Paul C ^b   Schmid, Christopher H ^b   Strandgaard, Svend ^b   Kamper, Anne Lise ^b   Maschio, Giuseppe ^b   Becicer, Gavin ^b   Perrone, Ronald D ^b   Levey, Andrew S ^b  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^b NONE

Author keywords

ACE inhibitors; Kidney disease progression; Polycystic kidney disease

Indexed keywords

ACEBUTOLOL; ATENOLOL; BENAZEPRIL; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NIFEDIPINE; RAMIPRIL;

ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DETERIORATION; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; KIDNEY POLYCYSTIC DISEASE; MEDLINE; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW;

EID: 10944247778     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00077.x     Document Type: Article

References (25)

1. GABOW PA: Autosomal dominant polycystic kidney disease. N Engl J Med 329:332-342, 1993
2. HUNSICKER LG, ADLER S, CAGGIULA A, et al: Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51:1908-1919, 1997
3. RUGGENENTI P, PERNA A, GHERARDI G, et al: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359-364, 1999
4. THE GISEN GROUP (GRUPPO ITALIANO DI STUDI EPIDEMIOLOGICI IN NEFROLOGIA): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
5. IHLE BU, WHITWORTH JA, SHAHINFAR S, et al: Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency. A controlled double-blind trial. Am J Kidney Dis 27:489-495, 1996
6. KANNO Y, SUZUKI H, OKADA H, et al: Calcium channel blockers versus ACE inhibitors as antihypertensives in polycystic kidney disease. Q J Med 89:65-70, 1996
7. RUGGENENTI P, PERNA A, GHERARDI G, et al: Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 35:1155-1165, 2000
8. ECDER T, EDELSTEIN CL, FICK-BROSNAHAN GM, et al: Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol 21:98-103, 2001
9. ECDER T, CHAPMAN AB, BROSNAHAN GM, et al: Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 35:427-432, 2000
10. VAN DIJK MA, BREUNING MH, DUISER R, et al: No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 18:2314-2320, 2003
11. JAFAR T, SCHMID C, LANDA M, et al: Angiotensin converting enzyme inhibitors and progression of non-diabetic renal disease: A metaanalysis of patient-level data. Ann Intern Med 135:73-87, 2001
12. ZUCCHELLI P, ZUCCALA A, BORGHI M, et al: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 42:452-458, 1992
13. KAMPER AL, STRANDGAARD S, LEYSSAC PP: Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens 5:423-430, 1992
14. VAN ESSEN GG, APPERLOO AJ, RENSMA PL, et al: Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney Int (Suppl 63):S58-S62, 1997
15. HANNEDOUCHE T, LANDAIS P, GOLDFARB B, et al: Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. Br Med J 309:833-837, 1994
16. BANNISTER KM, WEAVER A, CLARKSON AR, WOODROFFE AJ: Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol 111:184-193, 1995
17. HIMMELMANN A, HANSSON L, HANSSON BG, et al: Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy: ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension. Blood Press 4:85-90, 1995
18. MASCHIO G, ALBERTI D, JANIN G, et al: Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334:939-945, 1996
19. SCHMID CH, LANDA M, JAFAR TH, et al: Constructing a database of individual clinical trials for longitudinal analysis. Control Clin Trials 24:324-340, 2003
20. JAFAR TH, STARK PC, SCHMID CH, et al: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 60:1131-1140, 2001
21. VAN DIJK MA, PETERS DJ, BREUNING MH, CHANG PC: The angiotensin-converting enzyme genotype and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 10:1916-1920, 1999
22. CHAPMAN AB, JOHNSON AM, GABOW PA, SCHRIER RW: Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5:1349-1354, 1994
23. CHOUKROUN G, ITAKURA Y, ALBOUZE G, et al: Factors influencing progression of renal failure in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 6:1634-1642, 1995
24. BEEVERS G, LIP GY, O'BRIEN E: ABC of hypertension: Blood pressure measurement. Part II. Conventional sphygmomanometry: Technique of auscultatory blood pressure measurement. Br Med J 322:1043-1047, 2001
25. LEVEY AS, BOSCH JP, LEWIS JB, et al: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-470, 1999